Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Novel Coumarin-Based Acetohydrazide-1,2,3-Triazole Derivatives As Urease Enzyme Inhibitors: Synthesis, in Vitro Evaluation, and Molecular Dynamics Simulation Studies Publisher



Sepehrmansourie H1 ; Azimi M2 ; Ebadi A2, 3 ; Chehardoli G2, 3 ; Zolfigol MA4 ; Amanlou M5 ; Montazer MN5 ; Mahdavi M6 ; Najafi Z2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Converging Science and Technologies, University of Qom, Qom, Iran
  2. 2. Department of Medicinal Chemistry, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
  3. 3. Medicinal Plants and Natural Products Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
  4. 4. Department of Organic Chemistry, Faculty of Chemistry and Petroleum Sciences, Bu-Ali Sina University, Hamedan, Iran
  5. 5. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Heliyon Published:2025


Abstract

Urease enzyme inhibition is a well-established and promising strategy for preventing the harmful effects of ureolytic bacterial infections, particularly those caused by H. pylori. However, acetohydroxamic acid, the only approved urease inhibitor, has limited use due to significant side effects, including teratogenicity and psycho-neurological symptoms. To discover new inhibitors, novel coumarin-based acetohydrazide-1,2,3-triazole derivatives were synthesized and evaluated for their urease inhibitory activity. All tested compounds displayed remarkable anti-urease activity (IC50 = 1.62–16.91 μM) compared to thiourea as reference standard (IC50 = 23.11 ± 1.02 μM). The most potent derivative,(E)-N'-(4-((1-Benzyl-1H-1,2,3-triazol-4-yl)methoxy)benzylidene)-2-((4,7-dimethyl-2-oxo-2H-chromen-5-yl)oxy)acetohydrazide (13a), acted as an uncompetitive inhibitor with a Ki of 1.99 μM. The stable enzyme-inhibitor complex in molecular dynamics simulations (MD) indicated critical interactions between the ligand and the Cys592 and His593 residues, which stabilize the flap motif of the enzyme. Molecular dynamics simulations suggested that compound 13a tends to remain near the SER579-HIS593 α-helix rather than the nickel ions, stabilizing it in an open state. Thus, the MD studies confirmed the proposed mechanism of uncompetitive inhibition. Overall, these findings highlight the potential of coumarin-based acetohydrazide-1,2,3-triazole hybrids as potent and novel inhibitors for developing new therapeutics against urease-related diseases. © 2024 The Authors
Experts (# of related papers)